Kirk R Schultz Selected Research

Inflammation (Inflammations)

1/2023	Elevated ADA2 Enzyme Activity at the Onset of Chronic Graft-versus-Host Disease in Children.
1/2023	Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
1/2020	A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.
1/2018	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
1/2018	New Answers to Old Conundrums: What Antibodies, Exosomes and Inflammasomes Bring to the Conversation. Canadian National Transplant Research Program International Summit Report.
6/2015	Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kirk R Schultz Research Topics

Disease

33	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2024 - 01/2002
33	Bronchiolitis Obliterans Syndrome 03/2024 - 09/2004
27	Leukemia 01/2023 - 12/2003
25	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 01/2002
22	Neoplasms (Cancer) 04/2024 - 05/2003
10	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 12/2009
8	Residual Neoplasm 07/2023 - 11/2009
7	Infections 07/2023 - 11/2004
7	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020 - 07/2004
6	Philadelphia Chromosome 07/2023 - 11/2009
6	Inflammation (Inflammations) 01/2023 - 06/2015
6	Hematologic Neoplasms (Hematological Malignancy) 10/2021 - 11/2010
5	Acute Kidney Injury (Acute Renal Failure) 01/2024 - 01/2017
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 11/2010
4	Aplastic Anemia (Anemia, Hypoplastic) 01/2021 - 09/2011
4	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2013 - 09/2004
3	Chronic Renal Insufficiency 04/2024 - 01/2017
3	Hypertension (High Blood Pressure) 04/2024 - 01/2017
3	Kidney Diseases (Kidney Disease) 01/2023 - 01/2020
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2022 - 02/2010
3	Lymphoma (Lymphomas) 01/2020 - 09/2017
2	Hypokalemia 01/2023 - 10/2022
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 01/2020
2	Neuroblastoma 01/2020 - 02/2008
2	Neutropenia 02/2018 - 03/2013
2	Bone Marrow Failure Disorders 01/2018 - 10/2015
2	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 04/2006 - 12/2003
1	Heart Arrest (Cardiac Arrest) 07/2023
1	Central Nervous System Neoplasms 01/2023
1	Hypophosphatemia 01/2023
1	Mucositis 10/2022
1	Febrile Neutropenia 10/2022
1	Tumor Lysis Syndrome 10/2022
1	Capillary Leak Syndrome 01/2021
1	Central Nervous System Diseases (CNS Diseases) 10/2020
1	Hepatitis 01/2020
1	Pathologic Complete Response 01/2020
1	monosomy Chromosome 7 01/2020
1	Common Variable Immunodeficiency 01/2020
1	Wilms Tumor (Wilm's Tumor) 10/2018

Drug/Important Bio-Agent (IBA)

14	Biomarkers (Surrogate Marker)IBA 04/2024 - 02/2006
6	Cisplatin (Platino)FDA LinkGeneric 04/2024 - 01/2017
6	Imatinib Mesylate (Gleevec)FDA Link 07/2023 - 02/2008
5	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2018 - 02/2007
4	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2020
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2022 - 04/2006
4	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 02/2016
3	Abatacept (Orencia)FDA Link 04/2024 - 10/2021
3	ElectrolytesIBA 01/2024 - 01/2020
3	Dasatinib (BMS 354825)FDA Link 07/2023 - 01/2018
3	CreatinineIBA 01/2023 - 01/2020
3	Etoposide (VP 16)FDA LinkGeneric 11/2022 - 04/2006
3	AntigensIBA 01/2019 - 09/2012
3	Filgrastim (Neupogen)FDA Link 11/2017 - 01/2016
3	trans-crotonin (CTN)IBA 10/2017 - 08/2012
3	CytokinesIBA 12/2011 - 01/2002
2	Insulin-Like Growth Factor Binding ProteinsIBA 04/2024 - 01/2024
2	Alemtuzumab (Campath)FDA Link 01/2023 - 01/2019
2	nelarabine (506U78)FDA Link 11/2022 - 10/2020
2	Lipocalin-2IBA 01/2022 - 01/2017
2	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 02/2007
2	HLA-A Antigens (HLA-A)IBA 01/2020 - 11/2013
2	Calcineurin InhibitorsIBA 01/2019 - 01/2018
2	SteroidsIBA 01/2019 - 11/2009
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2018 - 09/2004
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2017 - 08/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2015 - 09/2011
2	Hemoglobins (Hemoglobin)IBA 03/2013 - 09/2003
2	HLA Antigens (Human Leukocyte Antigens)IBA 09/2011 - 11/2010
1	EnzymesIBA 01/2023
1	Mitochondrial DNA (mtDNA)IBA 01/2023
1	C-Reactive ProteinIBA 01/2023
1	NucleosidesIBA 11/2022
1	Plant NectarIBA 11/2022
1	ibrutinibIBA 11/2022
1	TOR Serine-Threonine KinasesIBA 10/2022
1	Alanine Transaminase (SGPT)IBA 10/2022
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2022
1	temsirolimus FDA Link 10/2022
1	Ketoglutaric Acids (Ketoglutaric Acid)IBA 01/2022
1	immunotoxin HA22IBA 01/2021
1	eltrombopag FDA Link 01/2021
1	Leucovorin (Folinic Acid)FDA Link 10/2020
1	pegaspargase (Oncaspar)FDA Link 10/2020
1	Phospholipases (Phospholipase)IBA 01/2020
1	Phospholipase C gammaIBA 01/2020
1	HLA-C Antigens (HLA-C)IBA 01/2020
1	HLA-B Antigens (HLA-B)IBA 01/2020
1	ponatinibIBA 01/2020
1	GNKG168IBA 11/2019
1	B-Cell Activating FactorIBA 01/2019

Therapy/Procedure

31	Transplantation 07/2023 - 01/2002
29	Cell Transplantation 12/2023 - 12/2008
28	Hematopoietic Stem Cell Transplantation 01/2023 - 12/2003
21	Therapeutics 04/2024 - 02/2006
9	Drug Therapy (Chemotherapy) 07/2023 - 05/2003
9	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2018 - 07/2004
4	Homologous Transplantation 01/2017 - 04/2006
3	Stem Cell Transplantation 07/2023 - 12/2009
1	Cell- and Tissue-Based Therapy (Cell Therapy) 03/2024